UK – Tecentriq hit with draft NICE rejection

The National Institute for Health and Care Excellence (NICE) has issued a new draft guidance, advising against the use of Roche's Tecentriq (atezolizumab) for adult patients with untreated extensive-stage small-cell lung cancer (SCLC).

The guidance, which denies the therapy routine NHS coverage, indicated that the PD-L1 inhibitor « meets NICE’s criteria to be considered a life-extending treatment at the end of life”, however “the cost-effectiveness estimates for Tecentriq with chemotherapy are higher than what is considered a cost-effective use of NHS resources. »

The watchdog also revealed that the “long-term benefit on overall survival is uncertain », as the mean cost of a course of treatment for a patient with extensive-stage SCLC is £32,798 at the list price.

Roche already has a commercial arrangement with the NHS that makes the drug available at a discount, but would have also applied to the extensive-stage SCLC indication had it been recommended…